2026 ASH®
Annual Meeting & Exposition December 12-15, 2026 ▪ New Orleans, Louisiana

Paper Details

Abstracts, authors, affiliations, and disclosures.

SESSION

101. Red Cells and Erythropoiesis, Excluding Iron: Poster I

Program: Poster Abstract Session
Saturday, December 12, 2026
05:30 p.m. - 07:30 p.m.
MCCNO - Hall F
Technology and Procedures, Assays, Molecular Testing, Omics Technologies, Cell Expansion, Treatment Considerations, Combination Therapy, Drug Development, Supportive Care, Therapy Sequence, Biological Therapies, Antibody Therapy, Immunotherapy, Adverse Events, Artificial Intelligence (AI), Machine Learning, Biological Processes, Pathogenesis, Genomics, Hematopoiesis, Immune Mechanism, Metabolism, Molecular Biology, Clinical Practice (Health Services and Quality), Clinical Guidelines, Health Economics, Diseases, Bleeding and Clotting, Thromboembolism, Thrombotic Disorders, Bone Marrow Failure Syndromes, Genetic Disorders, Hemoglobinopathies, Thalassemia, Immunology, Autoimmune Hemolytic Anemia, Infectious Diseases, Myeloid Malignancies, Metabolic Disorders, Research, Fundamental Science, Translational Research, Clinical Research, Clinical Trials, Epidemiology, Real-World Evidence, Registries, Study Population, Human, Adult, Pediatric, Young Adult
PAPER

1121 Erythropoietin rapidly remodels murine bone marrow by inducing early cell egress and disrupting B-cell lymphopoiesis

Albert Kolomansky, attending hematologist, Anton Gorodov2, Michelle Piper3, Lior Lezerovich4, Nathalie Ben-Califa5, Stav Kislev6, Howard S Oster, MD PhD7, Moshe Mittelman, MD8, Yankel Gabet, DMD PhD9, Drorit Neumann, PhD10
1 Assuta Ashdod University Hospital, Ashdod, Israel, Tel Aviv University, Tel Aviv, Israel
2 Tel Aviv University, Tel Aviv, Israel
3 Tel Aviv University, Tel Aviv, Israel
4 Tel Aviv University, Tel Aviv, Israel
5 Tel Aviv University, Tel Aviv, Israel
6 Tel Aviv University, Tel Aviv, Israel
7 Tel Aviv Sourasky Medical Center, Tel Aviv University, Tel Aviv, Israel
8 Tel Aviv Sourasky Medical Center, Tel Aviv University, Tel Aviv, Israel
9 Tel Aviv University, Tel Aviv, Israel
10 Tel Aviv University, Tel Aviv, Israel

Introduction: Erythropoietin (EPO) is a peptide hormone that controls red cell production, believed to act as an antiapoptotic signal. However, it also exerts pleiotropic effects on the immune and skeletal systems, including a profound effect on B cell homeostasis. Besides downregulation of IL-7, the mechanism for the latter effect and especially the role of B-cell specific EPOR signaling, are largely unclear. Here, we suggest a temporal scheme that describes EPO-induced remodeling of bone marrow (BM) populations, focusing on rapid egress-driven alterations as well as more gradual transcription-mediated effects leading to altered B-cell homeostasis.  

Methods: Both wild-type and transgenic mice harboring B-cell specific EPOR knockout (MB1-Cre; EPORfl/fl) or lineage tracing (MB1-Cre; ROSA-YFP) were used. EPO was administered as a single dose (180 IU) for short (16-48 h) or over 1 week (3 doses) for longer stimulation. BM cells were analyzed by flow cytometry and RNA seq with subsequent application of pathway analysis tools. We examined transdifferentiation by fluorescence microscopy.

Results: A single EPO injection induced rapid remodeling of the BM. Within 16 h, total BM B cells decreased by 26%, due to reduction in immature (IgM+) B cell fraction along with 14.5% reduction in TER119+ erythroid cells. This counterintuitive EPO-induced reduction in red cells was associated with modest but significant (4.6%) rise in hemoglobin, suggesting that egress-mobilization (E-M) of mature red cells is a primary mechanism of this hemoglobin boost. By 48 h, EPO-induced alterations also affected early B-cells, e.g. with ≈60% reduction in Pro-B cells. Reciprocal surges in the peripheral blood (PB) suggest that early B-cells are also subjected to E-M event. Importantly, unlike the effects observed with longer EPO stimulation, this early E-M was not associated with lower surface CXCR4 expression (as measured by MFI). After one week of EPO stimulation, BM B-cell depletion became more pronounced with a 42% reduction in total B cells predominantly affecting the IgM- fractions, i.e. Pro- and Pre-B cells, without further increase in PB. Notably, B-cell specific deletion of EPO-R (MB1-Cre;EPORfl/fl) did not attenuate these changes, indicating that EPO-induced disruption of B-cell homeostasis is largely independent of EPOR signaling. Similarly, EPOR deficiency did not alter the previously described EPO-mediated downregulation of IL7R on B220+ B cells.

To investigate the mechanism underlying disrupted B lymphopoiesis, we performed RNA sequencing of sorted B cell subsets, focusing on Pro- to Pre-B stages. This analysis revealed that while normal differentiation downregulates p53 signaling and upregulates neuroactive niche-sensing pathways, EPO treatment severely disrupts this developmental checkpoint. It uniquely induces an inflammatory interferon-related response while simultaneously halting essential DNA replication and homologous recombination repair machinery, leading to replication stress and inevitable apoptosis, which apparently compromises B-lymphopoiesis. Indeed, using caspase-3 labeling, we observed increased apoptosis in Pro-B cells with longer EPO stimulation. Interestingly, this apoptotic response was more pronounced in MB1-Cre;EPORfl/fl mice, suggesting that EPOR signaling in this context may partially protect developing B cells from EPO-induced stress. RNA-seq analysis also suggested increased developmental plasticity, including repression of PRC2-associated programs implicated in maintenance of B-cell lineage commitment. In this regard, we provide additional evidence for B cell-to-erythroid transition under EPO stimulation, using lineage tracing. Lineage-tracing experiments using sorted BM cells from EPO-treated MB1-Cre;ROSA-YFP mice showed the emergence of YFP+/TER119+ double-positive cells following EPO administration, providing additional evidence that EPO promotes B-cell-to-erythroid lineage transition.

Conclusions: EPO rapidly remodels murine BM by inducing coordinated egress-mobilization of erythroid and B-cell populations, followed by disruption of early B-cell development. These effects occur independently of B-cell autonomous EPOR signaling and are associated with transcriptional reprogramming, replication stress, increased apoptosis, and enhanced lineage plasticity. Together, our findings reveal previously unrecognized mechanisms by which EPO reshapes BM cellular composition that can be leveraged for clinical purposes.

Albert Kolomansky, attending hematologist: No relevant conflicts of interest to declare.